anti-AXL monoclonal antibody-MMAE conjugate

{
  "id": "MLC-T-ONC-010128",
  "term": "anti-AXL monoclonal antibody-MMAE conjugate",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC), consisting of a human monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) and conjugated, through a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of HuMax-AXL-ADC binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, MMAE is released into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization; this may result in G2/M phase arrest and apoptosis. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.",
  "abbreviation": "HuMax-AXL-ADC",
  "synonyms": [
    "anti-AXL/MMAE antibody-drug conjugate",
    "anti-AXL/MMAE ADC"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-axl-monoclonal-antibody-mmae-conjugate/"
}